Rob Robertson, Mba Email & Phone Number

Newtown, Pa, Us

Springfield, New Jersey, Us

Hatboro, Pennsylvania, Us

Express is a PE-Backed transportation asset management enterprise comprising one of the largest 4x4 truck fleets in the United States. - Headed capital budget and successfully grew revenues 60%. Grew assets 100% by establishing a Strategic Alliance with a major OEM.

Lan Pac comprises a 75,000 square foot manufacturing facility producing 1.5M square feet of corrugated packaging (boxes) per year.  Led company M&A process which led to the sale of Lan Pac at 6x EBITDA and grew revenues by 32% from 2017 to 2019 by signing a Strategic Alliance with a 3rd party corrugated enterprise. Implemented new financial reporting system that successfully reduced financial closing time by 50%. Executed Strategic Partnership with 3rd party that allowed revenues to grow 32% from 2017 to 2019.

Basel, Baselstadt, Ch

Novartis is a Swiss multinational pharmaceutical corporation with revenues of ~$48B in 2016. Over 12-year career at Novartis, led / participated in transactions that created ~ $10BN in shareholder value.  Rolled out innovative products at Novartis including Cosentyx (autoimmune medicine) with annual revenue streams of $4B+. Led / Participated in key deals such as Chiron, Idenix, Intercell, Nektar, Dynavax, and other smaller deals. Also led Novartis’ first transaction with a Chinese company with the acquisition of Zhejiang Tianyuan Vaccines.  Part of the 5-person leadership team that handled the M&A integration of Chiron into Novartis Vaccines & Diagnostics.  Led the annual M&A Strategy for Novartis General Medicines Division.  Led the largest competitive landscape analysis ever performed at Novartis. This project led to the acquisition of private company Corthera Therapeutics.  Supported the financial analysis (pricing, reimbursement, investment level) of the 2015 launch of key new product Cosentyx which went on to generate sales of approaching $4 Billion.

Basel, Baselstadt, Ch

Served as Finance lead on all US Pharmaceutical strategic option decisions. Conducted financial valuation in support of US Licensing Deals including in-licensing, out-licensing, divestitures, co-promotions, and acquisitions. Developed dynamic valuation models that incorporated risk and multiple scenarios options; and effectively negotiating team to communicate deal drivers and sensitivity analyses. Led annual M&A opportunity assessment project for US General Medicines. Analysis covered methodical review of Pharmaceutical landscape. Specific criteria established each year to identify the companies/compounds that best fit US General Medicines needs. Recommendations were presented to senior management leading to multiple acquisitions.  Conducted financial due diligence on over ten opportunities; assisted with term sheet and contract negotiations. Developed Commercial Financial Forecast review process to ensure precision and alignment with key forecast assumptions. Financial Forecast reviews would include Monte Carlo Simulation analysis where appropriate.

Basel, Baselstadt, Ch

Served as Head of Finance on all Global Vaccines & Diagnostics strategic option decisions. Lead a team of three that conducted financial valuation and due diligence in support of US Licensing Deals including in-licensing, out-licensing, divestitures, co-promotions, and acquisitions. Was co-chair of Deal Review Committee which presented opportunities to senior management monthly. Determined deal terms (upfront payment, milestone payments, royalty rates/tiers, and profit sharing) that attract partners while simultaneously mitigating risk for Novartis. Successfully participated in the closing of six transactions. Key point person in the negotiation team tasked to negotiate financial sections, terms, definitions, of contracts, and term sheets and stock purchase agreement. Led 2007 M&A strategy to evaluate opportunities and identify targets, which are presented to Board of Directors. Established criteria for standard and consistent methods of valuation; and effectively utilizes advanced Financial Theory in financial modeling when appropriate – Monte Carlo, Decision Tree, Real Options, and DCF/NPV analyses.

Basel, Baselstadt, Ch

Served as Finance lead on Global Pharmaceutical strategic option decisions. Conducted financial valuation in support of Global Licensing Deals including in-licensing, out-licensing, divestitures, co-promotions, and acquisitions. Developed dynamic valuation models that incorporated risk and multiple scenarios options; and effectively negotiating team to communicate deal drivers and sensitivity analyses. Key contributions included participating in the successful closing of five in-licensing deals and one out-licensing deal; determine appropriate deal terms and negotiating financial sections of contracts and term sheets. Developed and maintained the Global BD&L Finance Manual which served as an expert’s guide for all types of deals, acquisitions, and internal processes; this manual was used throughout the globe as a guide for valuation and all aspects of BD&L Finance.

 Conducted financial analysis to facilitate U.S. Human Health strategic business initiatives.  Integral in supporting Business Development and Merck Capital Ventures in designing and evaluating internal and external business opportunities, including acquisitions, licensing co-promotions, and divestitures.

 Served as primary financial support person for the Dermatology, Urology, Ophthalmology, Anti-Ulcercant Franchises, and the Specialty Sales Force while providing leadership and supervision to two senior financial institutions Analysts.  Partnered with F.B.G.s and Marketing Services to design annual Profit Plan, interim forecasts, and Long-Range Operating Plans for promotional expenses with a budget of less than $100 million.

Drafted and evaluated monthly results for U.S. Human Health sales and product costs, developed annual Profit Plan, interim forecasts, and Long-Range Operating Plan for U.S. Human Health sales and product cost.  Co-Launched Go-To-Market Strategy for Propecia (male pattern baldness medication) at Merck which generated ~$5.2B in revenue from 1999 – 2015.

Bachelor Of Science - Bs, Accounting, Finance, And Applied Mathematics

Master Of Business Administration - Mba, Finance And Marketing